deltatrials
Terminated PHASE1 NCT00075673

Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer

A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer

Sponsor: Case Comprehensive Cancer Center

Conditions Breast Cancer
Interventions celecoxib vinorelbine ditartrate
Updated 6 times since 2017 Last updated: Jul 23, 2020 Started: Nov 30, 2003 Primary completion: Sep 30, 2004 Completion: Feb 28, 2005

A PHASE1 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Case Comprehensive Cancer Center and has accumulated 6 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Aug 2020 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Jun 2018 — Aug 2020 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE1

    First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States